A Unique Clinical Case of Using Emicizumab as an Effective Therapeutic Approach for Refractory Acquired Hemophilia

MLA

Hambardzumyan, L., et al. “A Unique Clinical Case of Using Emicizumab as an Effective Therapeutic Approach for Refractory Acquired Hemophilia.” Hämostaseologie, vol. 44, no. 1, Number 1 Supplement 1, Feb. 2024. EBSCOhost, https://doi.org/10.1055/s-0044-1779135.

APA

Hambardzumyan, L., Pabinger, I., Tamamyan, G., Danelyan, S., Araqelyan, S., Petrosyan, L., Vardumyan, E., Sargsyan, N., & Khachatryan, H. (2024). A Unique Clinical Case of Using Emicizumab as an Effective Therapeutic Approach for Refractory Acquired Hemophilia. Hämostaseologie, 44(1, Number 1 Supplement 1). https://doi.org/10.1055/s-0044-1779135

Chicago

Hambardzumyan, L., I. Pabinger, G. Tamamyan, S. Danelyan, S. Araqelyan, L. Petrosyan, E. Vardumyan, N. Sargsyan, and H. Khachatryan. 2024. “A Unique Clinical Case of Using Emicizumab as an Effective Therapeutic Approach for Refractory Acquired Hemophilia.” Hämostaseologie 44 (1, Number 1 Supplement 1). doi:10.1055/s-0044-1779135.